Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Eli Lilly to acquire Phase 1/2 DICE Thera for US$2.4 Billion

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Jul 25, 2023 8:22pm

222 Views

Post# 35556918

RE:RE:RE:RE:RE:RE:RE:RE:RE:Eli Lilly to acquire Phase 1/2 DICE Thera for US$2.4 Billion

For those who want to think big on the infinitesimal. Search -- Beyond the atom - incredible plunge into the heart of the matter. Gives scope to the complexities at hand.

<< Previous

Bullboard Posts

Next >>

dynaCERT leans into global growth with new HydraGEN orders